Tumor types for which pazopanib/pazopanib is applicable

Pazopanib is an oral multi-target tyrosine kinase inhibitor (TKI) that mainly targets vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR), and has significant anti-angiogenic effects. Clinically, pazopanib is mainly approved for the treatment of two types of malignant tumors, namely metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma (STS). It has shown clear efficacy especially in patients who have previously received chemotherapy but have progressed.

In terms of metastatic renal cell carcinoma, pazopanib is one of the first-line treatment options and is suitable for patients who have not received previous systemic treatment or received cytotoxic chemotherapy. It delays disease progression by inhibiting angiogenesis and tumor cell growth signaling pathways, and has become a standard drug recommended by many guidelines.

Pazopanib is also widely used to treat advanced soft tissue sarcomas, especially common subtypes such as liposarcoma, synovial sarcoma, and leiomyosarcoma, if these patients still require subsequent treatment after failure of anthracycline-containing regimens. Although pazopanib is not suitable for all STS subtypes, it has become an important targeting option after chemotherapy for patients with certain pathological types.

In recent years, research has also extended the exploration of pazopanib's indications to other malignant solid tumors, such as thyroid cancer, ovarian cancer, pancreatic neuroendocrine tumors and certain lung cancer subtypes. Although it has not yet been widely approved, it has shown potential in some early clinical trials.

Generally speaking, the main applicable tumor types of pazopanib are metastatic renal cancer and advanced soft tissue sarcoma. It is one of the few oral targeted drug options for these two types of diseases. With its multi-target inhibition characteristics, it has broad development prospects in personalized tumor treatment.

Reference materials:https://www.votrient.com/